The estimated Net Worth of Erin Ator Thomson is at least $2.15 millió dollars as of 10 January 2022. Ms Thomson owns over 10,000 units of Shattuck Labs stock worth over $294,983 and over the last 4 years she sold STTK stock worth over $1,473,450. In addition, she makes $381,061 as Gen. Counsel at Shattuck Labs.
Ms has made over 10 trades of the Shattuck Labs stock since 2020, according to the Form 4 filled with the SEC. Most recently she exercised 10,000 units of STTK stock worth $29,500 on 10 January 2022.
The largest trade she's ever made was selling 33,000 units of Shattuck Labs stock on 19 October 2021 worth over $643,500. On average, Ms trades about 5,689 units every 33 days since 2020. As of 10 January 2022 she still owns at least 79,084 units of Shattuck Labs stock.
You can see the complete history of Ms Thomson stock trades at the bottom of the page.
Erin Ator Thomson J.D. is the Gen. Counsel at Shattuck Labs.
As the Gen. Counsel of Shattuck Labs, the total compensation of Ms D at Shattuck Labs is $381,061. There are 6 executives at Shattuck Labs getting paid more, with Dr. Arundathy Nirmalini Pandite M.B.A., M.D. having the highest compensation of $583,002.
Ms D is 41, she's been the Gen. Counsel of Shattuck Labs since . There are 4 older and 2 younger executives at Shattuck Labs. The oldest executive at Shattuck Labs, Inc. is Dr. Arundathy Nirmalini Pandite M.B.A., M.D., 62, who is the Chief Medical Officer.
Erin's mailing address filed with the SEC is C/O SHATTUCK LABS, INC., 500 W. 5TH STREET, SUITE 1200, AUSTIN, TX, 78701.
Over the last 4 years, insiders at Shattuck Labs have traded over $14,634,250 worth of Shattuck Labs stock and bought 3,526,605 units worth $60,008,520 . The most active insiders traders include Group, Llc Green Jeremy Red..., Clay B Siegall és Josiah Hornblower. On average, Shattuck Labs executives and independent directors trade stock every 25 days with the average trade being worth of $300,381. The most recent stock trade was executed by Tyler Brous on 27 June 2024, trading 8,416 units of STTK stock currently worth $32,738.
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also holds a collaboration agreement with Takeda Pharmaceuticals to develop SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.
Shattuck Labs executives and other stock owners filed with the SEC include: